eight month requirement is warranted. If the information were not collected the Commission's information regarding actual loading of frequencies would be inaccurate.

OMB Control No.: 3060–0286.
Expiration Date: 4/30/2001.
Title: 80.302 Notice of discontinuance, reduction, or impairment of service involving a distress watch.
Form Number: Not applicable.
Estimated Annual Burden: 160 hours; 1 hour per respondent; 160 respondents.
Description: This rule is needed to ensure that the U.S. Coast Guard is informed when a coast station discontinues, reduces or impairs a listening watch required to be maintained on a marine safety frequency.

OMB Control No.: 3060–0330.
Expiration Date: 4/30/2001.
Title: Part 62—Applications to Hold Interlocking Directorates.
Form Number: N/A.
Estimated annual burden: 20 hours; 2 hours per response; 10 respondents.
Description: Congress mandated this information collection under 47 USC 212 to be conducted by the FCC to monitor the effect of interlocking directorates on the telecommunications industry and to ensure they will not have any anticompetitive impact.

OMB Control No.: 3060–0361.
Expiration Date: 4/30/2001.
Title: 80.29 Changes during license term.
Form Number: Not applicable.
Estimated annual burden: 250 hours; 1 hour per response; 250 respondents.
Description: The information is used by the FCC to update the coast and ship station license files and data base concerning current name and address of licensees. Information concerning changes in the names of vessels is also used to update the ITU List of Ship Stations.

OMB Control No.: 3060–0807.
Expiration Date: 4/30/2001.
Title: 47 CFR Section 51.803 and Supplemental Procedures for Petitions Pursuant to Section 252(e)(5) of the Communications Act of 1934, as amended.
Form Number: Not applicable.
Estimated annual burden: 2,040 hours; 39.23 hours (average) per response; 52 respondents.
Description: Any interested party seeking preemption of a state commission's jurisdiction based on the state commission's failure to act shall notify the Commission (47 USC 252(e)(5) and 47 CFR Section 51.803). In a Public Notice the Commission set out procedures for filing petitions for preemption pursuant to section 252(e)(5). All the information will be used to ensure that petitioners have complied with their obligations under the Communications Act of 1934, as amended.

Federal Communications Commission.

Magalie Roman Salas,

Secretary.

[FR Doc. 98–13811 Filed 5–22–98; 8:45 am]

BILLING CODE 6712–01–P

FEDERAL MARITIME COMMISSION

[Petition P3–98]

In Re: The Impact of Modern Technology on the Customs and Practices of the Freight Forwarding Industry—Petition for Rulemaking; Notice of Filing of Petition

Notice is given that a petition for rulemaking or, alternatively, for a declaratory order, has been filed by R.F. International Ltd. (''Petitioner''). Petitioner seeks a rulemaking to address and evaluate the impact of modern technology on the customs and practices of the freight forwarding industry and the regulations governing those customs and practices. Petitioner seeks review of guidelines regarding freight forwarding, freight forwarding fees, and freight forwarder compensation in view of trends in high-technology freight forwarding and seeks guidelines for the provision of ''in-plant'' forwarding services provided by licensed freight forwarders.

In the event of denial of this petition for rulemaking, Petitioner requests that this petition be treated as a request for a declaratory order to allow Petitioner to act without peril on its own view.

Interested persons are requested to reply to the petition no later than June 25, 1998. Replies shall specify the desired disposition of the petition and to the extent applicable, shall specify the substance of any rule or order supported. Replies shall be directed to the Secretary, Federal Maritime Commission, Washington, D.C. 20573–0001, shall consist of an original and 15 copies, and shall be served on counsel for Petitioner, Leonard L. Fleisig, Esq. Eckert, Seamans, Cherin and Mellott LLC, 1250 24th Street, N.W., Suite 700, Washington, D.C. 20007.

Copies of the petition are available for examination at the Washington, D.C. Office of the Secretary of the Commission, 800 N. Capitol Street, N.W., Room 1046.

Joseph C. Polking,

Secretary.

[FR Doc. 98–13842 Filed 5–22–98; 8:45 am]

BILLING CODE 6730–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Committee on Immunization Practices: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: Advisory Committee on Immunization Practices (ACIP).
Times and Dates: 8:15 a.m.–6:15 p.m., June 24, 1998; 8:00 a.m.–4:00 p.m., June 25, 1998.
Place: CDC, Auditorium B, Building 2, 1600 Clifton Road, NE, Atlanta, Georgia 30333.
Status: Open to the public, limited only by the space available.
Purpose: The Committee is charged with advising the Director, CDC, on the appropriate uses of immunizing agents. In addition, under 42 U.S.C. 1396s, the Committee is mandated to establish and periodically review and, as appropriate, revise a list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) Program, along with schedules regarding the appropriate periodicity, dosage, and contraindications applicable to the vaccines.
Matters to be Discussed: Agenda items include a summary of the meeting on ''Evaluating the Role of Vaccines and Infectious Diseases in Autoimmune Disease: Insulin Dependent (Type 1) Diabetes Mellitus'; updates on the National Immunization Program; the Vaccine Injury Compensation Program; the National Vaccine Program; and HIV vaccine. Also on the agenda, a discussion of financial disclosure and voting protocol for ACIP; rotavirus vaccine data on differences in morbidity by socioeconomic group, update on cost benefit data, use of vaccine in premature infants, and rotavirus disease in immunocompromised persons; a review of changes in the draft rabies vaccine recommendation; computer algorithms for ACIP recommendations; hepatitis A vaccine; consolidate resolutions currently included in the VFC Program; harmonizing recommendation on combination vaccines with the American Academy of Pediatrics and the American Academy of Family Physicians; use of lyme disease vaccine; progress towards development of a revised influenza recommendation; and intravenous immunoglobulin products. Other matters of relevance among the Committee's objectives may be discussed.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Gloria A. Kovach, Committee Management Specialist, CDC, 1600 Clifton Road, NE, M/S D50, Atlanta, Georgia 30333, telephone 404/639–7250.

Dated: May 19, 1998.

Nancy C. Hirsch,

Acting Director, Management Analysis and Services Office Centers for Disease Control and Prevention (CDC).

[FR Doc. 98–13847 Filed 5–22–98; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Care Financing Administration

Statement of Organization, Functions and Delegations of Authority

Part F, of the Statement of Organization, Functions, and Delegations of Authority of the Department of Health and Human Services, Health Care Financing Administration (HCFA), 49 FR 34247, dated September 6, 1984, is amended to include the following delegation of authority from the Secretary to the Administrator, HCFA, for the Federal Technology Transfer Act of 1986.

- Section F.30., Delegations of Authority is amended by adding the following paragraph:

TT. The authorities vested in the Secretary by the Stevenson-Wydler Technology Innovation Act of 1980, as amended by the Federal Technology Transfer Act of 1986, the National Technology Transfer and Advancement Act of 1995 and subsequent amendments.

This delegation shall be exercised under the Department's existing delegation of authority and policy on regulations. In addition, I hereby affirm and ratify any actions taken by the HCFA Administrator or other HCFA officials which, in effect, involved the exercise of this authority prior to the effective date of this delegation.

This delegation is effective immediately.

Dated: May 15, 1998.

Donna E. Shalala,

Secretary, Department of Health and Human Services.

[FR Doc. 98–13809 Filed 5–22–98; 8:45 am]

BILLING CODE 4120–03–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of General Medical Sciences; Submission for OMB Review; Comment Request; Application for the Pharmacology Research Associate Program

Summary: Under the provisions of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the National Institute of General Medical Sciences (NIGMS), the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request to review and approve the information collection listed below. This proposed information collection was previously published in the **Federal Register** on March 3, 1998, page 10404, and allowed 60 days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment. The National Institutes of Health may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number.

Proposed Collection

Title: Application for the Pharmacology Research Associate Program. *Type of Information Collection Request:* Revision of a currently approved collection. *Need and Use of Information Collection:* The Pharmacology Research Associate (PRAT) Program will use the applicant and referee information to award opportunities for training and experience in laboratory or clinical investigation to individuals with a Ph.D degree in pharmacology or a related science, M.D., or other professional degree through appointments as PRAT Fellows at the National Institutes of Health or the Food and Drug Administration. The goal of the program is to develop leaders in pharmacological research for key positions in academic, industrial, and Federal research laboratories. *Frequency of Response:* Once a year. *Affected Public:* Individuals or households; businesses or other for-profit.

The annual reporting burden is as follows:

Type and number of respondents	Estimated number of responses per respondent	Estimated total responses	Average burden hours per responses	Estimated total annual burden hours requested
Applicants: 50	1	50	2.00	100
Referees: 150	1	150	0.167	25

Total Number of Respondents: 200.
Total Number of Responses: 200.
Total Hours: 125.

The annualized cost to respondents is estimated at:

Applicants: $5,500.00.
Referees: $1,250.00.

Request for Comments

Written comments and/or suggestions from the public and affected agencies should address one or more of the following points: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

Direct Comments To OMB

Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the Office of Management and Budget, Office of Regulatory Affairs, New Executive Office Building, Room 10235, Washington, D.C. 20503, Attention: Desk Officer for NIH. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Ms. Sally Lee, NIGMS, NIH, Natcher Building Room 3AS–13, 45 Center